- Home
- PLX vs WLAC Comparison
PLX vs WLAC Comparison
Compare PLX & WLAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- WLAC
- Stock Information
- Founded
- PLX 1993
- WLAC 2024
- Country
- PLX United States
- WLAC United States
- Employees
- PLX N/A
- WLAC N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- WLAC
- Sector
- PLX Health Care
- WLAC
- Exchange
- PLX Nasdaq
- WLAC Nasdaq
- Market Cap
- PLX 160.2M
- WLAC 172.6M
- IPO Year
- PLX 1998
- WLAC 2024
- Fundamental
- Price
- PLX $1.55
- WLAC $10.14
- Analyst Decision
- PLX Strong Buy
- WLAC
- Analyst Count
- PLX 1
- WLAC 0
- Target Price
- PLX $15.00
- WLAC N/A
- AVG Volume (30 Days)
- PLX 1.4M
- WLAC 6.9K
- Earning Date
- PLX 05-09-2025
- WLAC 01-01-0001
- Dividend Yield
- PLX N/A
- WLAC N/A
- EPS Growth
- PLX N/A
- WLAC N/A
- EPS
- PLX 0.05
- WLAC N/A
- Revenue
- PLX $59,764,000.00
- WLAC N/A
- Revenue This Year
- PLX $65.02
- WLAC N/A
- Revenue Next Year
- PLX $57.34
- WLAC N/A
- P/E Ratio
- PLX $32.18
- WLAC $749.45
- Revenue Growth
- PLX 0.18
- WLAC N/A
- 52 Week Low
- PLX $0.82
- WLAC $9.80
- 52 Week High
- PLX $3.10
- WLAC $10.60
- Technical
- Relative Strength Index (RSI)
- PLX 30.32
- WLAC N/A
- Support Level
- PLX $1.52
- WLAC N/A
- Resistance Level
- PLX $1.79
- WLAC N/A
- Average True Range (ATR)
- PLX 0.09
- WLAC 0.00
- MACD
- PLX -0.01
- WLAC 0.00
- Stochastic Oscillator
- PLX 26.44
- WLAC 0.00
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About WLAC Willow Lane Acquisition Corp. Class A Ordinary Shares
Willow Lane Acquisition Corp is a blank check company.